Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-21	US$2.285	+0.22%	3,031
26-08-20	US$2.280	-1.72%	9,489
26-08-19	US$2.320	+2.21%	25,397
26-08-18	US$2.270	-0.00%	6,659
26-08-17	US$2.270	+4.13%	14,413

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.280USD

Average target price

11.50USD

Spread / Average Target

+404.39%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq 14:38:50 2026-08-21 EDT			5-day change	1st Jan Change
2.285 ^USD	+0.22%		+4.82%	-33.58%

08-12	Vyome Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-01	Vyome Receives China Patent for Besifloxacin Acne Gel	MT

Market Cap	16M 13.71M 12.83M 11.74M 22.03M 1.53B 22.32M 152M 59.09M 769M 60.09M 58.78M 2.54B	P/E 2026 *	-3.23x	P/E 2027 *	-2.49x
Enterprise Value	16M 13.71M 12.83M 11.74M 22.03M 1.53B 22.32M 152M 59.09M 769M 60.09M 58.78M 2.54B	EV / Sales 2026 *	107x	EV / Sales 2027 *	64x
Free-Float	47.12%	Yield 2026 *	-	Yield 2027 *	-

08-12	Vyome Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-01	Vyome Receives China Patent for Besifloxacin Acne Gel	MT
06-23	Vyome Holdings, Inc., Q1 2026 Earnings Call, Jun 03, 2026
05-12	Vyome Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Vyome strikes deal with Impetis Biosciences, opening a ~$57B market opportunity	RE
04-22	Vyome Holdings, Inc. Presents Transformational VT-1953 Phase 2 Clinical Study Data	CI
04-06	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026	CI
03-18	Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-24	Livechain completes acquisition of senior, secured debt of Humanyze	RE
02-11	Vyome files for VT-1953 orphan drug status, furthers strategic focus on VT-1953 program over the next 6 months	RE
02-02	Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results	RE
12-08	Vyome reports positive final Phase 2 results for VT-1953, plans to advance into pivotal study for FDA approval	RE
12-08	Vyome Holdings, Inc. Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval	CI

24-07-17	Maxim Downgrades ReShape Lifesciences to Hold From Buy	MT
22-08-01	Maxim Group Adjusts ReShape Lifesciences Price Target to $1.50 From $3, Maintains Buy Rating	MT
22-05-26	Alliance Global Adjusts Price Target on ReShape Lifesciences to $4.65 From $5.50, Reiterates Buy Rating	MT
22-03-29	Maxim Lowers Price Target for ReShape Lifesciences to $4 From $8, Maintains Buy Rating	MT
22-03-29	Alliance Global Adjusts Price Target on ReShape Lifesciences to $5.50 From $10.25, Reiterates Buy Rating	MT

Vyome Holdings, Inc. Stock

Stocks

HIND

US92943X1046

Biotechnology & Medical Research

Valuation: Vyome Holdings, Inc.

Chart: Vyome Holdings, Inc.

Latest news : Vyome Holdings, Inc.

Last Transcript: Vyome Holdings, Inc.

Analysts' recommendations: Vyome Holdings, Inc.

Press Releases: Vyome Holdings, Inc.

News in other languages: Vyome Holdings, Inc.

Quotes and Performance

Course Extremes

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-01	Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio	BU
05-28	Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet	BU
05-12	Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity	BU
04-22	Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026	BU
04-06	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026	BU

23-12-13	Wall Street op nieuwe jaarrecords gesloten
23-12-13	Wall Street in afwachting van rentebesluit
23-12-13	Licht hogere start voor Wall Street

1 day	-0.22%
1 week	+4.82%
Current month	+8.04%
1 month	+4.82%
3 months	+2.47%
6 months	-21.21%
Current year	-33.58%

1 week	2.13	2.36
1 month	1.97	2.36
Current year	1.75	3.89
1 year	1.75	12
3 years	1.75	16
5 years	1.75	16
10 years	1.75	16

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/13/25	Venkateswarlu Nelabhotla	Free	Founder	615,149	11.1972%
11/13/25	John Tincoff	Free	Director	17,833	0.3246%
11/13/25	Shiladitya Sengupta	Free	Founder	624,432	11.3662%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VYOME HOLDINGS, INC.	+0.22%	+4.82%	-79.15%	-	16M
LONZA GROUP AG	+1.09%	+5.26%	+4.44%	+26.03%	51.22B
REVOLUTION MEDICINES, INC.	-1.45%	+2.16%	+470.50%	+596.75%	45.38B
BEONE MEDICINES AG	+2.14%	+8.25%	+19.80%	+91.79%	41.97B
IQVIA HOLDINGS INC.	+1.07%	+9.23%	+39.44%	+20.59%	42.15B
CELLTRION, INC.	-0.93%	-4.80%	+17.39%	+46.60%	31.95B
ASCENDIS PHARMA A/S	+0.36%	+2.85%	-	-	16.73B
MEDPACE HOLDINGS, INC.	+1.71%	+7.96%	+37.76%	+153.89%	17.1B
EUROFINS SCIENTIFIC SE	+0.03%	+3.41%	+7.12%	+35.49%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.54%	+5.37%	+90.95%	+46.88%	13.91B
Average	+0.52%	+3.43%	+67.58%	+127.25%	27.52B
Weighted average by Cap.	+0.53%	+3.13%	+103.09%	+148.71%

	2026 *	2027 *
Net sales	150K 128K 120K 110K 207K 14.35M 209K 1.42M 554K 7.21M 563K 551K 23.85M	250K 214K 200K 183K 344K 23.92M 349K 2.37M 923K 12.02M 939K 918K 39.74M
Net income	-4.89M -4.19M -3.92M -3.59M -6.73M -468M -6.82M -46.31M -18.06M -235M -18.36M -17.96M -777M	-7.77M -6.65M -6.23M -5.7M -10.7M -743M -10.84M -73.57M -28.69M -373M -29.17M -28.54M -1.24B
Net Debt	-	-